On March 15, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, talked on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in Small-Molecule Drug Design’ at the AI in Drug Discovery 2021.
Categories
Recent Posts
- Denovicon Selected for DOE National Lab Collaboration on Quantum–Photonic Drug Discovery
- Denovicon Reports Discovery of DNT-1569: A Highly Potent and Selective Small-Molecule PARP7 Inhibitor for Immuno-Oncology
- Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs
- Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator
- Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network